Irritable Bowel Syndrome
Conditions
Brief summary
Irritable bowel syndrome is the most common functional gastrointestinal disease and is characterized by high prevalence and chronic course.The pathology has a strong impact on the quality of life of affected patients and on health and social costs, these related to reduced productivity.The scarce efficacy and heavy side effects of traditional therapies lead these patients to often resort to alternative or complementary therapies. From the evaluation of the evidence of various probiotic preparations and food supplements, the investigators have used a commercial preparation characterized by the presence of bifidobacteria which have demonstrated some efficacy in thinking of improving the quality of life of these patients to evaluate quality of life, ability productivity and trend of some indices of disease severity in a small number of patients. These preliminary data could represent a starting point for more in-depth evaluations, also with placebo-controlled studies.
Interventions
Probiotic Formula
Sponsors
Istituto Clinico Humanitas
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients aged ≥18 years * Diagnosis of IBS according to Rome IV criteria * Mild to moderate disease, as measured by FBDSI * Absence of signs and symptoms that may suggest organic damage and, if indicated, negative instrumental investigations (colonoscopy and/or imaging) * Prescription of Bifidice, according to normal clinical practice * Informed consent expressed in written form
Exclusion criteria
* Patients undergoing surgical resection of the stomach, gallbladder, small or large intestine * History of inflammatory bowel disease * Severe SII, measured by FBDSI * Active peptic ulcer * History of ischemic colitis * Active infectious enteritis * Diagnosed with hypo- or hyperthyroidism * Need for pharmacological treatments for IBS, antibiotics, antidepressants and laxatives * Therapy in progress with drug or supplements included in the list of those not allowed (Paragraph N: to be established) * Any disease that may affect gastrointestinal function and could interfere with appropriate assessment of abdominal pain or discomfort
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Modification of teh intestinal microbiota | 12 months | Analysis of faecal samples (Next Generation Sequencing analysis) |
Countries
Italy
Outcome results
None listed